Screener
Pacific Biosciences of California PACB Ratios & Valuation
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 36.4%+15.0pp | 37.5%+21.3pp | 28.6%+4.4pp | 25.4%+4.2pp | 21.4%-2.3pp | |
| Operating margin | -83.5%+359pp | -83.3%+456pp | -346.2%-38.2pp | -430.6%-195pp | -442.6%-216pp | |
| Net margin | -82.5%+256pp | -80.3%+353pp | -341.5%-139pp | -327.3%-99.6pp | -338.7%-127pp | |
| Efficiency | ||||||
| Asset turnover | 0.2×+0.1× | 0.2×+0.1× | 0.2×+0.1× | 0.1×0.0× | 0.1×0.0× | |
| Liquidity | ||||||
| Current ratio | 4.9×-2.0× | 5.7×-1.0× | 5.1×-2.3× | 6.2×-3.5× | 6.9×-1.1× | |
| Per Share | ||||||
| Book value per share | -$0.11-152% | $0.01-97.5% | $0.02-99.0% | $0.12-92.8% | $0.20-88.7% | |
| Valuation | ||||||
| Market capitalization | $368.06M-5.6% | $398.64M+13.4% | $564.57M+4.8% | $384.47M-17.0% | $360.1M-2.5% | |
| Price / sales | 2.3×-0.2× | 2.5×+0.2× | 3.5×0.0× | 2.5×-0.2× | 2.3×+0.4× |
FAQ
- What are Pacific Biosciences of California's profit margins?
- Pacific Biosciences of California (PACB) runs a 36.4% gross margin and a -83.5% operating margin, with a -82.5% net margin.
- Where do Pacific Biosciences of California's ratios come from?
- Every ratio is computed from Pacific Biosciences of California's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
